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Changes in cellular functions in response to drug therapy are mediated by specific transcriptional profiles resulting
from the induction or repression in the activity of a number of genes, thereby modifying the preexisting gene activity
pattern of the drug-targeted cell(s). Recombinant human interferon beta (rIFNb) is routinely used to control
exacerbations in multiple sclerosis patients with only partial success, mainly because of adverse effects and a relatively
large proportion of nonresponders. We applied advanced data-mining and predictive modeling tools to a longitudinal
70-gene expression dataset generated by kinetic reverse-transcription PCR from 52 multiple sclerosis patients treated
with rIFNb to discover higher-order predictive patterns associated with treatment outcome and to define the molecular
footprint that rIFNb engraves on peripheral blood mononuclear cells. We identified nine sets of gene triplets whose
expression, when tested before the initiation of therapy, can predict the response to interferon beta with up to 86%
accuracy. In addition, time-series analysis revealed potential key players involved in a good or poor response to
interferon beta. Statistical testing of a random outcome class and tolerance to noise was carried out to establish the
robustness of the predictive models. Large-scale kinetic reverse-transcription PCR, coupled with advanced data-mining
efforts, can effectively reveal preexisting and drug-induced gene expression signatures associated with therapeutic
effects.
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Introduction
Interferons are small, inducible proteins secreted by
nucleated cells in response to viral infection and other
stimuli. They act in a paracrine fashion on other cells in
their immediate vicinity, triggering a state of growth arrest,
so that infected cells cannot be forced to produce viral
proteins, and activating the process of programmed cell
death, so that infected cells can be removed [1]. Interferons
are important not only in the defense against a wide range
of viruses but also in the regulation of immune responses
and hematopoietic cell development [2,3]. Recombinant
human interferon beta (rIFNb) is routinely used to control
exacerbations in relapsing-remitting multiple sclerosis (MS)
[4,5]. Although effective in reducing the number of
exacerbations and brain disease activity in some patients,
rIFNb produces no benefit in almost one-half of these
patients [6,7]. Furthermore, it is not at all certain how
significant its long-term effects on disease progression are.
Therapy has been associated with a number of adverse
reactions, including flu-like symptoms, transient laboratory
abnormalities, menstrual disorders, increased spasticity, and
dermal reactions [8].
We generated and analyzed longitudinal patterns of gene
expression from interferon beta (IFNb)–treated patients
suffering from MS with the aim of identifying preexisting
and drug-induced signatures that would predict or explain
the clinical response to the drug.
Results/Discussion
Fifty-two patients with relapsing-remitting MS were fol-
lowed for at least 2 y after initiation of therapy with IFNb.
Clinical follow-up included a neurological examination every
3 mo and at the time of relapse. At each visit, a blood sample
was obtained by venipuncture. After the 2-y endpoint,
patients were classified as either good or poor responders
based on strict criteria, as described in Materials and
Methods. We measured the expression profile of 70 carefully
selected genes from peripheral blood mononuclear cells
isolated from each patient at each time point, using one-step
kinetic reverse-transcription PCR (Dataset S1). This process
offers remarkable sensitivity and specificity and a dynamic
range of several orders of magnitude, allowing the compar-
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ison of expressed transcripts from many different genes
without compromising accuracy. Targets for analysis were
selected on the basis of their presumed biological action and
included genes coding for type I and II IFN-responsive
molecules, cytokine receptors, members of the interferon
(IFN) signaling and apoptosis pathways, and several tran-
scription factors involved in immune regulation (Table S1).
Altogether, more than 70,000 reactions were carried out. A
common inherent prediction performance limitation of most
high-throughput gene-expression profiling projects arises
from the largely asymmetric expression data matrix obtained
as a result of measuring far more genes than samples [9]. Such
ill-conditioned data matrices inevitably lead to overfitting of
predictive models (among other difficulties), some effects of
which can be mitigated by judicious application of various
established inverse and regularization schemes [10]. The
undesirable properties (i.e., overfitting) of such massively
under-determined datasets are largely avoided in this study
design because the number of genes measured is commen-
surable with the numbers of samples.
Using linear discriminant analysis–based integrated Baye-
sian inference system (IBIS), we were able to detect the gene
MX1 as the single best discriminating variable between
samples obtained at baseline (T = 0) and at 3 mo after
initiation of therapy (T = 3) with a classification accuracy of
79% (data not shown). Given that MX1 is a known marker of
IFN bioavailability [11], this result validates our experimental
approach as well as our sample handling and processing.
To search for expression signatures associated with
therapeutic outcome (good or poor responder), we con-
ducted clustering of samples using normalized data for all 70
genes at each time point [12]. Despite applying several
different similarity measures and clustering algorithms [13],
we did not observe concomitant segregation of samples
according to their responder status, with the exception of a
few local clusters of small size (Figure 1). This result may
suggest that overall differences in gene expression in the two
groups of patients, as assessed by conventional similarity
measures, are small or negligible. The clustering null results
with respect to concomitant class segregation, however, do
not rule out the possibility of discovering outcome-predictive
combinatorial and nonlinear relationships. To investigate
this possibility further, we used quadratic discriminant
analysis–based IBIS, implemented for three-dimensional
Figure 1. Nonsupervised Two-Way Hierarchical Clustering of Samples at T = 0
A clear aggregation of samples cannot be seen by this technique. The first column indicates the type of responder to which each sample belongs
(red, good; blue, poor).
DOI: 10.1371/journal.pbio.0030002.g001
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(3D) searches, in the search for highly predictive sets of three
genes whose expression at T = 0 correlated with a good or
poor outcome of therapy at the 2-y endpoint. This process
exhaustively carried out sample classification by searching
through all 54,740 possible three-gene combinations of 70
genes. Higher-order combinatorial searches beyond combi-
nations of three genes are possible using IBIS and are
currently under investigation. However, higher-order pre-
dictive variable combinations do require the support of many
more samples to prevent overfitting of the model.
We implemented a stringent method for examining the
statistical validity of our classification results that consisted in
testing the obtained classifier in an independent set of
samples not previously ‘‘seen’’ by the program. All of the
following statistical analyses were thus performed on split
datasets, namely, training (75% of the samples) and test
(25%), each reflecting the same relative proportion of classes
(63% good and 37% poor responders). We started by
conducting 3D IBIS searches using expression data from only
the training set and selected the top nine scoring triplets (on
the basis of their high prediction accuracy and low mean
squared error [MSE] values). For each gene triplet, and using
the training data only, a committee of classifiers was built
based on an internal cross-validation scheme. Subsequently,
the classifiers were used to predict the outcome of an
independent test set of samples. Gene triplets were ranked
on the basis of the prediction accuracies of the classifiers on
this independent test set. We identified nine gene triplets
with a predictive accuracy of at least 80% (Table 1). We
considered it essential to empirically rule out the chances of
fortuitous data splits in the accuracy results obtained from
the top-scoring gene triplets.
Consequently, for the nine top-scoring gene triplets and
their corresponding classifiers, we generated 100 random
splits and built classifiers for each new resulting training set.
Next, we tested how well the classifiers predicted therapeutic
outcome in the corresponding test datasets. Figure 2
illustrates the distribution in the prediction accuracies
obtained for the triplet composed of Caspase 2, Caspase 10,
and FLIP, which yielded a predictive accuracy of 86% in the
original split. The bell-shaped distribution resulting from 100
tests for this triplet displayed a mean accuracy of 87.8% and a
tenth percentile of 78.6%, meaning that if the prediction
were performed multiple times, in 90% of these instances an
accuracy of almost 79% or better would be obtained. This
histogram only reflects the range of accuracies obtained,
should the initial data split be different. Notably, the genes in
the top-scoring triplet were Caspase 2, Caspase 10, and FLIP—
three apoptosis-related molecules. The second-highest-scor-
ing triplet was that of Caspase 2, Caspase 3, and IRF4 (86.8%
Table 1. Best-Scoring Predictors of Response to IFNb at T = 0
Gene Triplet
Set Gene Gene Gene Mean (100) Mean (500) After Noisea
1 Caspase 2 Caspase 10 FLIP 87.8 86.9 76.5
2 Caspase 2 Caspase 3 IRF4 86.8 87.5 79.3
3 Caspase 2 Caspase 7 IRF4 85.1 84 71.6
4 IL4Ra Caspase 2 IRF4 84.6 83.7 73.6
5 Caspase 10 IRF4 MAP3K1 84.2 83.8 75.6
6 IL12Rb1 Caspase 10 MAP3K1 83.6 84.7 74.9
7 STAT4 Caspase 2 IRF2 83.2 82.4 69.5
8 IL4Ra Caspase 2 Caspase 3 80.8 79.5 73.5
9 Caspase 2 IRF4 IRF6 80.6 80.8 70.3
For each triplet, the mean prediction accuracy for 100 and 500 splits of the data are shown. Prediction was recalculated after the addition of Gaussian noise to each expression value.
a The percentage drop in prediction accuracy after the addition of noise.
DOI: 10.1371/journal.pbio.0030002.t001
Figure 2. Accuracy Ranges of the Three-Gene Predictive Model of IFNb
Response
After the initial data split into training and test sets, using IBIS on the
training set only, nine best-performing triplets were identified. The
triplet of Caspase 2, Caspase 10, and FLIP resulted in an accuracy rate
of 86% correct prediction on the blind test set resulting from the
original split. To minimize the effect of fortuitous initial data division
in the accuracy outcome, an extra 100 data splits were performed as a
coarse approximation of the possible ranges of accuracies in which
this gene triplet could result. A histogram of prediction accuracy over
the 100 trials for the gene triplet composed of Caspase 2, Caspase 10,
and FLIP is shown as an example of classification and prediction of
response to IFNb at T = 0. A red Gaussian curve encompasses the
distribution, where the mean prediction accuracy was 87.9%, with a
maximum of 100% (in 11 cases) and a minimum of 64.3% (in two
cases). The broken blue line indicates the tenth percentile (78.6%).
No major differences were found when we performed the same
classification/prediction strategy in 500 random splits of the data.
DOI: 10.1371/journal.pbio.0030002.g002
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mean accuracy after 100 splits). Other high-scoring triplets
included IL4Ra and MAP3K1, in addition to other apoptotic
molecules (Table 1). When we repeated this experiment with
the top three scoring genes, using F-test, the obtained mean
accuracy was 64% (tenth percentile at 50%) (Figure 3).
In Figure 4, the predictive capability of the best-scoring
triplet (Caspase 2, Caspase 10, and FLIP; 3D model) was
compared with those obtained with the single-gene (1D)
and gene-pair (2D) models. We observed that the classifica-
tion accuracy improves as more genes are added to the
classifier. We next plotted the samples of a test dataset (25%
of samples) on the predictive probability model shown in
Figure 4G and compared the performance of the 3D IBIS
model to those of the individual 2D models (Figure 5).
Overall, the 2D projections of the 3D predictive model show
that the Caspase 2/Caspase 10 and Caspase 10/FLIP gene pairs
show significant predictive capability, but that all three genes
are required to provide the highest level of model accuracy
and robustness.
To validate the specificity and predictive capability of the
top-scoring gene triplet (for the good and poor responding
classes) and its associated classifiers, we examined the model
exhibiting the best performance on a ‘‘default’’ expression
dataset. This null dataset was built keeping the original gene
expression data and randomly permuting the class labels of
the outcomes 1,000 times (keeping the same counts of good
and poor responding patients as were in the original dataset).
The prediction accuracies for all the gene triplets obtained
with this dataset dropped dramatically as the means ranged
from 49.2% to 53.6% (data not shown), emphasizing the
specificity of the classifiers. In addition, for the top-scoring
gene triplet (for good and poor responder classes), we
calculated the probability of achieving, under the null
hypothesis, an equal or better accuracy than that obtained
in the original prediction (86%), as previously described [14].
This achieved significance level was 0.009, suggesting that it is
very unlikely that the prediction accuracies observed for this
classifier are caused by chance.
Finally, we tested the robustness of each of these gene sets
as predictors of IFNb response by simulating experimental
measurement error. To accomplish this, we first calculated
the standard deviation of the expression measurements for all
genes as an estimation of the overall experimental error. We
then added a fixed amount of Gaussian noise corresponding
to one standard deviation (taken from 20 random deviations)
to each expression value and repeated the classification/
prediction in 30 different splits of the data (a total of 600
tests). Notably, the mean drop in predictive accuracy after the
addition of noise was less than 10%, denoting a significant
tolerance to reasonable measurement errors (Table 1).
Because all the patients in this study were systematically
followed up for a period of 2 y, we were able to perform a
longitudinal analysis. Using a repeated-measures analysis of
variance (ANOVA), we searched for genes with significantly
different expression patterns based on models that tested for
responder effect, time effect, and interaction effect (time 3
response).
Significant responder effect for 20 genes (Figure 6) and
significant time effect for 13 genes were detected (Figure 7).
Interestingly, six of the genes that showed statistically
significant differences between good and poor responders,
IRF4 (p = 0.03), IL4Ra (p = 0.01), Caspase 10 (p = 0.0008),
Caspase 7 (p = 0.01), IRF2 (p = 0.02), and IRF6 (p = 0.03) are
among the 12 genes that best predict response at T = 0
(shown in bold in Figure 7B). A pattern consistent with
increased apoptosis (five members of the Caspase family of
Figure 3. Best-Scoring Gene Triplet by F-Test Analysis
Notably, as observed with IBIS, Caspase 10 was also the single best discriminant (p = 1.873 104) variable, but the second and third best scoring
genes by F-test (IL12Rb2, IL4Ra) did not seem to add any significant predictive power. The mean prediction accuracy for the test set of samples
was 65.6% (tenth percentile, 57.1%), well below that observed for the triplet derived from IBIS (Caspase 2, Caspase 10, and FLIP) shown in Figure 2.
This suggests that F-test could efficiently capture individual linear separators but cannot identify and prioritize the nonlinear combinations of
genes discovered by IBIS that ultimately provide the most predictive accuracy and robustness.
DOI: 10.1371/journal.pbio.0030002.g003
PLoS Biology | www.plosbiology.org January 2005 | Volume 3 | Issue 1 | e20169
Prediction of the Response to IFNb
PLoS Biology | www.plosbiology.org January 2005 | Volume 3 | Issue 1 | e20170
Prediction of the Response to IFNb
proteins, TRADD, and BAX) was observed for the poor
responders.
Although we successfully identified informative, combina-
torial relationships, establishing the causality of the associa-
tion between gene expression and outcome to therapy is
beyond of the scope of this work, and these genes are
therefore considered surrogate markers. Moreover, although
extensive in vivo and in vitro experiments have been
conducted, the full mechanism of action of IFNb in MS
remains unknown.
Transcription profiling experiments have involved IFNb in
the regulation of apoptosis in both cancer and MS
[15,16,17,18]. Induction of programmed cell death could lead
to a reduction in the number of activated lymphocytes,
macrophages, and monocyte-derived dendritic cells—all key
components of the pathogenic process leading to tissue
damage in MS [19,20,21]. However, increased levels of some
anti-apoptotic molecules have also been observed in IFNb-
treated MS patients, possibly reflecting a compensatory
mechanism [16]. Furthermore, even the inhibition of acti-
vated T cell apoptosis in response to IFNa and IFNb has been
reported [22]. Our finding of increased apoptosis in poor
responders does not support the hypothesis of programmed
cell death as a primary therapeutic mechanism for IFNb. We
hypothesize that a net increase in pro-apoptotic transcripts
in peripheral blood mononuclear cells from poor responders
could be reflecting undesired elimination of certain regu-
latory cell populations that are much needed to maintain a
homeostatic balance.
Other differentially expressed transcripts included IRF4, a
gene essential for mature T and B lymphocyte function and
homeostasis, and a transcription factor with dual function
(activator/repressor) that regulates transcription of IL4
through physical interaction with NFATc2 [23]. Remarkably,
IRF4 is a repressor of other IFN-induced genes [24], an
observation consistent with the elevated expression of IRF4
observed in the poor responders before initiation of therapy.
As expected, the gene MX1 showed a significant time effect
independent of clinical response (p = 0.01). This result is in
agreement with previous findings indicating substantial MX1
upregulation in response to type I IFNs [25]. Interestingly,
upregulation of MX1, which occurs minutes after IFN
stimulation [26], is sustained over at least 2 y, spanning
several orders of magnitude of time units. This also correlates
well with our results identifying MX1 as the best single
classifier for samples from patients before (T = 0) and after
(T = 3) initiation of therapy. In fact, as Figure 7 illustrates,
most of the significance for the time effect in MX1 comes
from the difference between T = 0 and T = 3.
Also of interest, a significant time effect (but not
responder effect) was observed for IFNAR1 and STAT2
(Figure 7B). Because IFNAR1 is a subunit of the hetero-
dimeric type I IFN receptor and STAT2 is a critical
component of the DNA binding complex ISGF3a (which
regulates the expression of IFN-responsive genes), their
upregulation on administration of rIFNb is likely related to
mechanistic aspects of IFN signaling. Our results suggest that
poor response is associated with downstream signaling
events rather than deficient recognition or metabolism of
the drug. Our previous finding that IFN receptor poly-
morphisms do not affect therapeutic response in this same
set of patients partially supports this hypothesis [27]. Only
two genes with significant time effects, Caspase 10 (p = 0.01)
and MAP3K1 (p = 0.01) were part of any predictor set
(Figure 7B). In addition, MAP3K1 also showed a significant
interaction effect (p = 0.05; data not shown). These results
highlight the involvement of these genes in the response to
IFN both at T = 0 and once therapy has started.
Here we combined large-scale, function-oriented gene
expression with advanced data mining to identify a set of
markers that accurately and robustly predict the response to
rIFNb therapy.Although larger, prospective studies areneeded
to confirm these findings, our results suggest that the under-
lying gene activity profile of an individual at the verge of
therapyharbors sufficient information to allow investigators to
estimate the chances of experiencing satisfactory therapeutic
effects. As analytical tools topredict clinical outcomes basedon
molecular evidence evolve, these types of studies are likely to
become a substantial aid to the physician, taking the paradigm
of personalized medicine one step further.
Materials and Methods
Patients and samples. All studies were approved by the respective
Committees of Human Research at Hospital Vall d’Hebron, Barce-
lona, Spain, and the University of California, San Francisco, United
States. Informed consent was obtained for all study participants. All
patients were examined by a trained neurologist at the CNI Unit, Vall
d’Hebron Hospital. Inclusion criteria for this study were clinically
definite MS (Poser’s criteria), disease in relapsing-remitting phase,
age between 18 and 65 y, recorded history of at least two clearly
identified relapses within the preceding 24 mo, and expanded
disability status scale between zero and 5.5 (inclusive). Detailed
information about clinical aspects of these patients has been recently
reported elsewhere [6].
Patients were categorized as good responders (n = 33) if they
experienced a total suppression of relapses and no increase in the
expanded disability status scale after a 2-y follow-up period. Poor
Figure 4. Training Dataset Performance of the Three Genes from the Top Predictive Model of IFNb Response
One-, two-, and three-dimensional IBIS searches were conducted independently on the same training dataset. Each chart shows a two-colored
background, corresponding to regions predictive of good response (red) and poor response (blue). Each colored dot corresponds to an
individual sample (red, good responder; blue, poor responder).
(A–C) One-dimensional IBIS predictive models. High values of Caspase 10 are associated with poor response according to a linear relationship. In
contrast, Caspase 2 levels are associated with poor response at intermediate values, suggesting a nonlinear relationship. FLIP expression is
associated with good responders at low values, again depicting a linear relationship. The highest cross-validation accuracy score for a single gene
predictor was 73% (Caspase 10).
(D–F) Two-dimensional IBIS predictive models. Each of the three possible pairs of this classifier was tested. Linear and nonlinear combinatorial
predictive relationships were revealed, specifically, a nonlinear predictive relationship associating poor response with high values of Caspase 10
and intermediate values of Caspase 2, a nonlinear relationship associating good response with high values of FLIP and either low or high (but
notintermediate) values of Caspase 2, and a linear relationship associating poor response with low values of FLIP and high values of Caspase 10.
The highest cross-validation score was obtained for the Caspase 2/Caspase 10 pair according to a nonlinear, quadratic distribution (85% accuracy).
(G) Three-dimensional IBIS predictive model. The shapes identified in the 1D and 2D distributions were optimized by the 3D model, providing a
better separation of good and poor responders.
DOI: 10.1371/journal.pbio.0030002.g004
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responders (n = 19) were defined as having suffered two or more
relapses or having a confirmed increase of one point in the expanded
disability status scale score. Patients with intermediate phenotypes
were excluded from this study. Blood specimens were taken following
institutional guidelines at approximately the same time of the day
just before the administration of the first dose of rIFNb and every 3
mo thereafter during the neurological examination, with the
exception of T = 15 and T = 21 mo. Altogether, 336 samples were
tested (an average of 6.5 time points along 2 y for each individual).
Immediately after being drawn, all blood samples were spun over
Ficoll-Paque (Amersham Biosciences, Piscataway, New Jersey, United
States) gradients to enrich the sample for mononuclear cells. After
three washes with PBS, aliquots of 5 3 106 cells were frozen in
RPMI1640 containing 20% DMSO and 20% fetal calf serum.
RNA purification, quantitation, and handling. Peripheral blood
mononuclear cells were thawed at 37 8C for 1 min, and RNA lysis
buffer was added immediately. RNA was purified with the Strataprep
kit (Stratagene, La Jolla, California, United States) and finally
resuspended in nuclease-free water (Promega, Madison, Wisconsin,
United States). One-microliter RNA aliquots were subjected to
fluorescence-based quantitation (in duplicate) using the Ribogreen
reagent (Molecular Probes, Eugene, Oregon, United States) in a
Spectra Max Gemini fluorometer (Molecular Devices, Sunnyvale,
California, United States). Samples were diluted to 1 ng ll1 using
nuclease-free water, and 5 ll was aliquoted in triplicates into 384-well
plates using a Multiprobe II liquid-handling instrument (PerkinElmer
Life and Analytical Sciences, Boston, Massachusetts, United States).
Plates were kept frozen at 70 8C until needed.
One-step kinetic reverse-transcription PCR. A master mix was
prepared essentially as described previously [28], with the addition of
200lMROX(Sigma, St. Louis,Missouri,United States), andoverlaidon
top of each well of a freshly thawed 384-well plate containing 5 ng of
RNA in each well. Reactions were performed in triplicate using an ABI
7900 Sequence Detection System (Applied Biosystems, Foster City,
California, United States). Positive and negative controls, as well as
calibration curves, all in triplicate, were also included in each reaction
plate. Total reaction volume was 10 ll. All expression values were
calculated by interpolation in a calibration curve spanning five orders
of magnitude constructed with an in vitro transcribed clone of
GAPDH. The average of each expression measurement was then
divided by that of one of the positive controls (thymusRNA) to account
for plate-to-plate variability. On the basis of reports addressing the
limited utility of normalization [29,30] and of our unpublished
observations, we avoided housekeeping gene normalization and used
instead RNA content, thus relying on repeated precise fluorescence-
based quantitation and highly accurate liquid-handling procedures.
Data collection and analysis. A custom Microsoft Excel (Microsoft,
Redmond, Washington, United States) worksheet was prepared for
handling reaction data import and performing initial statistics.
Normalized data were imported as a .csv file into GeneLinker Platinum
(Predictive Patterns Software, Kingston, Ontario, Canada) for prepro-
cessing and clustering analysis. Quadratic discriminant analysis–based
IBIS implemented for 3D searches was carried out at the School of
Computing, Queen’s University, Kingston, Ontario, Canada, and at
Biosystemix, Sydenham, Ontario, Canada. IBIS is a data-mining
algorithm that searches through the gene space for a single gene (or
group of genes) that can predict the outcome class (in this case, good
and poor response to rIFNb therapy). This algorithm incorporates a
complete 10-fold cross-validation method with several independently
trained classifiers topredict an outcomeon the basis of a voting scheme
(see below). We usedMSE and classification accuracy to assess how well
the classification predictionsmatched the true response of the patients
to therapy. The top-performing gene triplets were selected on the basis
of a mixed threshold for low MSE levels and high accuracy rates.
The algorithm. IBIS identifies genes (or gene pairs or groups of
genes) that are highly predictive of the outcome based on probability
distributions of those genes in different outcome classes. For example,
for a given gene gi, twoGaussian functions are fitted to the distributions
of the observed expression levels in good responding and poor
responding patients (let us call these fitted distributions Dg and Dp
for good and poor responding patients, respectively). Our fitted
distribution, Dg(x), denotes the probability of a patient having an
expression level of gi = x, given that this patient is a good responder.
The fundamental question we are aiming to answer using data-mining
methods (here using IBIS particularly) is as follows: what is the
probability of a patient being a good responder given the observed
expression level of a gene for that patient? Taking advantage of the
fitted distributions, a classifier applies Bayes’ formula to answer the
fundamental question. According to this formula:
PðPagood responderjðgi ¼ xÞÞ ¼
Pððgi ¼ xÞjPagood responderÞPðPagood responderÞ
P1 þ P2 ; ð1Þ
where P1 = P((gi = x)jPagood_responder)P(Pagood_responder). In fact,
P((gi = x)jPagood_responder) is the distribution function fitted to the ob-
served gene expression values of gi above (Dg), and P(Pagood_responder),
the probability of a patient being a good responder, can be easily
calculated using the total and good responding patient counts. The
term P2 is strictly analogous to P1 but applies to poor responders.
Therefore, according to equation 1, for a given gene, a comprehensive
model is built that predicts the probability of a patient being a good
responder for different values of observed expressions of that gene.
IBIS searches through all the genes and calculates such models for a
single gene or combination of genes, resulting in singular or
combinatorial mining of most relevant genes. The probability of a
patient being a poor responder can also be calculated in a similar
fashion.
To obtain a reliable classifier that is generalizable to all patient
samples obtained under similar conditions, the Gaussian distribu-
tions and the classifier were only trained on a subsample of the
patient data (training set). The results of the classification (i.e.,
probability of a patient being a good or poor responder), however,
were tested on patient samples never seen by the classifier before (test
set). This ensures limitation of the classifier overfitting. Further, a
complete 10-fold cross-validation scheme was built into the training
phase. In IBIS, linear and quadratic classifiers correspond to
classifiers built using Gaussian distributions with equal or different
covariance matrices, respectively. The prediction results of IBIS are
visualized graphically within the observed gene expression space by
presenting the probabilities of a patient being a good or poor
responder as a background color (see Figures 4 and 5). The red
background in the gene space represents a high probability of a
patient sample being a good responder if the observed gene
expression values are in that range in the gene space. The blue
background, similarly, represents a high probability of a patient
sample being a poor responder if the observed gene expression values
are in that range in the gene space.
Several measures were used to assess how well the calculated
probabilities matched the true patient responses to therapy. Two of
these measures were MSE and classification accuracy. MSE was
calculated as the sum of (responsei
observed  responseiexpected)2
Figure 5. Test Dataset Performance of the Top Three-Gene Predictive Model of IFNb Response
The same probability model generated from the training dataset (see Figure 4G) provides the background shading of volumes predictive
of good response (red) and poor response (blue). Three samples are identified with arrows and followed along different graphical
representations.
(A and B) The two rotations of the full 3D model show that all good responder samples are correctly classified.
(C–E) Two-dimensional IBIS predictive models. Three samples are identified with arrows and followed along different graphical representations.
If prediction was performed in only two dimensions, a higher number of misclassifications would have occurred. For example, the 2D model
built using only Caspase 2/FLIP (C), could not resolve the good responding sample identified by a cyan arrow, whereas it correctly resolves the
good responding sample shown by the orange arrow. The model built using Caspase 10/FLIP (D), in contrast, acts oppositely and can resolve the
good responding sample shown by the cyan arrow and not the sample shown by the orange arrow. Both these sample are correctly resolved the
2D model built using Caspase 2/Caspase 10 (E); however, this model is unable to resolve the poor responding sample identified by the yellow arrow,
whereas one of the previous models (D) was able to do this. As demonstrated in the full 3D model view from (A) and (B), all the labeled poor and
good responding patients are correctly classified. Although 2D models show high predictive capabilities, all three genes are needed to increase
the classification accuracy of the IBIS model.
DOI: 10.1371/journal.pbio.0030002.g005
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averaged over all patients. For a given patient, the clinical response
determined by the end of the 2-y monitoring period is denoted by
responsei
observed and responsei
expected and represents the probability
of that patient being a good responder to rIFNb therapy, using the
Bayes’ formula above. Classification accuracy simply expresses the
percentage of patients that were correctly predicted as being good or
poor responders.
Classification and prediction procedure. The initial dataset of
patients was divided into two parts; namely, a training set with 75%
of the samples and a test set with 25% of the samples, each reflecting
the same proportion of classes (63% good and 37% poor responders).
Only the training set was used for identifying the best predictive gene
triplets with the IBIS method, as well as for building the classifier. A
committee of classifiers was then generated using a 10-fold cross-
Figure 6. Characteristic Gene Expression Profiles of Good and Poor Responders to IFNb over Time
(A) An unsupervised hierarchical clustering representation of the weighted difference between the average expression of good and poor
responders. For each gene, the obtained differences were log normalized and multiplied by the F-statistic from an ANOVA (responder effect)
run previously (shown in [B]). The ‘‘heat’’ colored bar represents the absolute value of this difference. With the exception of MX1 (indicated by
an arrow), all genes showing a significant difference in expression between the two groups of patients were automatically arranged in only two
clusters (framed in blue).
(B) List of all genes showing a significant responder effect along with their F-statistic and p-values. Genes that were part of any triplet showing
more than 80% prediction accuracy at T = 0 are shown in bold.
(C) A continuous representation of the longitudinal average expression of two representative genes for good (8) and poor () responders.TRADD shows two widely parallel curves, indicative of a significant difference in the expression averages, correlating with its profile (#) observed
in the clustering shown in (A). In contrast, GATA3 displays two almost overlapping curves, consistent with its shading (*) in the clustering in (A).
DOI: 10.1371/journal.pbio.0030002.g006
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validation scheme during training. The training data themselves were
divided into ten parts, and each time, a classifier was built using only
nine parts of the data. That classifier’s predictive capability was
determined by its accuracy over the one-tenth of the data withheld. A
committee of ten classifiers was assembled from the results of this
training stage; this committee was then applied to the test data (which
have thus far been hidden from the classifiers). For a patient sample
in the test data, each classifier in the committee made a prediction. A
majority voting scheme then decided as to which class the sample
would be assigned.
Given the initial data split into training and test sets, it was
important to rule out the role of fortuitous idiosyncrasies in this split
and the resulting accuracy rates. To address this point, we created 100
random splits of the data into training and test subgroups. A
committee of classifiers was trained on the training set for each data
split, and the accuracies were calculated over the blind test set. A
histogram of the test set accuracies was then built, representing the
expected ranges of accuracies had the initial data split been different.
This histogram is not representative of the estimated or idealized
distribution of the accuracies for a gene triplet in a machine learning
sense. Rather, it is a coarse approximation of the possible range of
gene triplet outcome–prediction accuracies that could be expected.
Controlling for false discoveries. To assess the significance and
specificity of the top-scoring gene triplets and their corresponding
trained committee of classifiers, a null dataset was created by keeping
the same expression levels of genes in the dataset and randomly
permuting the class labels of the patients 1,000 times (the total count
of poor and good responding patients was unchanged). Classifiers
were built using the training null data, and accuracies were calculated
on the corresponding test sets. The mean of these accuracies for all
the top-performing gene triplets was around 50%. The achieved
significance level, which represents the probability of achieving
Figure 7. IFNb-Induced Changes in Gene Expression over Time
(A) An unsupervised hierarchical clustering representation of the weighted difference in gene expression at each time point versus baseline. For
each gene, the obtained differences were log normalized and multiplied by the F-statistic from an ANOVA (time effect) run previously (shown in
[B]). The ‘‘heat’’ colored bar represents the absolute value of this difference. With the exception of IFNAR1 (arrow), all genes showing a
significantly different expression in at least one time point with respect to baseline were arranged in the same cluster (framed in blue).
(B) List of all genes showing a significant time effect along with their F-statistic and p-values. Genes that were part of any triplet showing more
than 80% prediction accuracy at T = 0 are in bold.
(C) A continuous representation of the longitudinal average expression of two representative genes over all samples. MX1 (8) shows a markeddeparture from T = 0 and remains elevated for the rest of the observed period. This correlates well with the shading (#) displayed in the
clustering shown in (A). In contrast, IRF6 () displays an almost flat curve, consistent with its color in the clustering (*).
DOI: 10.1371/journal.pbio.0030002.g007
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accuracy levels better than or equal to that of the nonpermuted
classification, was calculated to be 0.009. This value can be considered
a significance level, or p-value, and indicates the number of times in
1,000 trials for which accuracies of 86% or higher can be achieved
under the ‘‘no predictive capability’’ null hypothesis.
Time-series analysis was performed using SAS version 8.0 (SAS
Institute, Cary, North Carolina, United States). Permutation analysis
and histogram graphic outputs were produced with Matlab (The
Mathworks, Natick, Massachusetts, United States).
Supporting Information
Dataset S1. Raw Expression Dataset
Gene expression values for all samples at all time points. This is the
raw file from which all analyses were performed.
Found at DOI: 10.1371/journal.pbio.0030002.sd001 (491 KB XLS).
Table S1. Target Information
Gene names, symbols, and LocusLink and GenBank accession
numbers, as well as primer sequences, are listed for all targets.
Found at DOI: 10.1371/journal.pbio.0030002.st001 (160 KB DOC).
Accession Numbers
The LocusLink (http://www.ncbi.nlm.nih.gov/projects/LocusLink/) ac-
cession numbers for the genes discussed in this paper are BAX (LLID
581), Caspase 10 (LLID 843), Caspase 2 (LLID 835), Caspase 3 (LLID 836),
Caspase 7 (LLID 840), FLIP (LLID 8837), IFNAR1 (LLID 3454), IL4
(LLID 3565), IL4Ra (LLID 3566), IRF2 (LLID 3660), IRF4 (LLID 3662),
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